Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Orexo, a Swedih pharmaceutical company focused on improved pharmaceuticals and digital therapies, announced that it will partner with Lyfebulb, a...
Orexo's partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI...
Orexo AB (publ.) today announces it has acquired the exclusive US rights to GAIA AG's (GAIA) deprexis®, a digital therapy to help patients manage...
Q1 2020 highlights Total net revenues of SEK 175.0 m (174.3), up 0.4 percent EBITDA of SEK 39.1 m (12.0), up 225.8 percent Net earnings of SEK 82.6 m ...
Orexo AB (publ.) today announces the appointment of James Noble as Chairman of the Board. The resolution was taken today at the annual general...
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the extraordinary general meeting, to be held...
Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on 16 April 2020 resolved, in accordance with the...
The board of directors of Orexo AB (publ) has resolved to withdraw the previously communicated proposals to the annual general meeting 2020...
Orexo AB (publ) has ended the program to repurchase its own ordinary shares that was announced on February 17, 2020. A total of 500,000 shares,...
Annual Report, including the Sustainability Report, for the 2019 fiscal year has been published. The Annual Report can be downloaded on the company's ...
Orexo AB (publ.) has repurchased 14 percent of its outstanding unsecured corporate bonds with a nominal value of SEK 40,500,000 through several...
Orexo AB (publ.), today hosts a Capital Market Day in Stockholm, Sweden. On the day the company will present an overview of the company's growth...
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on...
As previously communicated, Orexo invites investors, analysts and the media to participate in the company's Capital Markets Day in Stockholm, Sweden, ...
Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable...
Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden, on...
The board of Orexo AB (publ.) has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019, to initiate a...
Q4 2019 highlights Total net revenues of SEK 238.1 million (227.1), up 4.8 percent Zubsolv® US net revenues of SEK 190.5 million (166.7), up 14.3...
Orexo AB (publ.) today announces promising results from its OX338 pharmacokinetic study, evaluating novel formulations of ketorolac, a non-addictive, ...
Orexo AB (publ.), the fully integrated specialty pharmaceutical company with the aim of becoming a leader in the treatment of addiction, today...
Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today...
Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will...
Strong financials paving the way for broadening the business UPPSALA, Sweden, Oct. 24, 2019 Q3 2019 highlights Total net revenues of SEK 231.2...
Prior to the Annual General Meeting (AGM) in 2020, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.